{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:52:11Z","timestamp":1788871931077,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ygyno.2014.03.014","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T20:30:09Z","timestamp":1395433809000},"page":"446-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer"],"prefix":"10.1016","volume":"133","author":[{"given":"Kelly","family":"Fust","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maschio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Barron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton C.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Parthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Walli-Attaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.03.014_bb0005","doi-asserted-by":"crossref","DOI":"10.3111\/13696998.2013.782034","article-title":"A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia","author":"Dulisse","year":"2013","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.ygyno.2014.03.014_bb0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.03.014_bb0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","article-title":"Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma","volume":"77","author":"Wildiers","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.03.014_bb0020","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2011.05.023","article-title":"Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer","volume":"122","author":"Fauci","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.03.014_bb0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ygyno.2014.03.014_bb0030","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.03.014_bb0035","series-title":"Amgen","author":"NEUPOGEN\u00ae (Filgrastim) prescribing information","year":"2013"},{"issue":"1","key":"10.1016\/j.ygyno.2014.03.014_bb0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.03.014_bb0045","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.03.014_bb0050","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1345\/aph.1G516","article-title":"Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?","volume":"40","author":"Weycker","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ygyno.2014.03.014_bb0055","series-title":"Amgen","author":"Neulasta\u00ae (pegfilgrastim) prescribing information","year":"2010"},{"key":"10.1016\/j.ygyno.2014.03.014_bb0060","series-title":"Myeloid, growth factors","volume":"v1","author":"NCCN Guidelines","year":"2013"},{"issue":"19","key":"10.1016\/j.ygyno.2014.03.014_bb0065","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2014.03.014_bb0070","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1525-1438.2007.00915.x","article-title":"Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma\u2014a cost-effectiveness analysis","volume":"17","author":"Numnum","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.03.014_bb0075","series-title":"Ovarian Cancer","volume":"v2","author":"Guidelines","year":"2013"},{"issue":"2","key":"10.1016\/j.ygyno.2014.03.014_bb0080","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.03.014_bb0085","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/gyno.1997.4787","article-title":"Topotecan in platinum- and paclitaxel-resistant ovarian cancer","volume":"66","author":"Swisher","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"14","key":"10.1016\/j.ygyno.2014.03.014_bb0090","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1200\/JCO.2000.18.14.2733","article-title":"Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma","volume":"18","author":"Verschraegen","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2014.03.014_bb0095","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdm438","article-title":"Pegfilgrastim+\/\u2212ciprofloxacin for primary prophylaxis with TAC (docetaxel\/doxorubicin\/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study","volume":"19","author":"von Minckwitz","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2014.03.014_bb0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jval.2010.10.037","article-title":"Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom","volume":"14","author":"Whyte","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.ygyno.2014.03.014_bb0105","first-page":"1","article-title":"United States life tables, 2007","volume":"59","author":"Arias","year":"2011","journal-title":"Natl Vital Stat Rep"},{"issue":"1","key":"10.1016\/j.ygyno.2014.03.014_bb0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000335604","article-title":"Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer","volume":"58","author":"Weycker","year":"2012","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1016\/j.ygyno.2014.03.014_bb0115","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.clinthera.2009.05.003","article-title":"Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States","volume":"31","author":"Lyman","year":"2009","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.ygyno.2014.03.014_bb0120","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.03.014_bb0125","series-title":"Cost-effectiveness in health and medicine","author":"Gold","year":"1996"},{"issue":"10","key":"10.1016\/j.ygyno.2014.03.014_bb0130","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/00001813-199811000-00009","article-title":"Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients","volume":"9","author":"Brown","year":"1998","journal-title":"Anticancer Drugs"},{"issue":"15","key":"10.1016\/j.ygyno.2014.03.014_bb0135","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/jnci\/djt182","article-title":"Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients","volume":"105","author":"Lathia","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ygyno.2014.03.014_bb0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice","volume":"6","author":"Crawford","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.ygyno.2014.03.014_bb0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-006-9254-4","article-title":"Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy","volume":"100","author":"Shayne","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ygyno.2014.03.014_bb0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"9","key":"10.1016\/j.ygyno.2014.03.014_bb0155","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMsa054744","article-title":"The value of medical spending in the United States, 1960\u20132000","volume":"355","author":"Cutler","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ygyno.2014.03.014_bb0160","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","article-title":"Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Flowers","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2014.03.014_bb0165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0959-8049(93)90169-G","article-title":"The impact of received dose intensity on the outcome of advanced ovarian cancer","volume":"29A","author":"Repetto","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.03.014_bb0170","article-title":"Primary versus secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses","author":"Hill","year":"2013","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.ygyno.2014.03.014_bb0175","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1524-4733.2007.00242.x","article-title":"Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy","volume":"11","author":"Eldar-Lissai","year":"2008","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.ygyno.2014.03.014_bb0180","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/03007990802636817","article-title":"Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States","volume":"25","author":"Lyman","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.ygyno.2014.03.014_bb0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1524-4733.2008.00434.x","article-title":"Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy","volume":"12","author":"Ramsey","year":"2009","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.ygyno.2014.03.014_bb0190","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1634\/theoncologist.6-5-441","article-title":"Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients","volume":"6","author":"Calhoun","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2014.03.014_bb0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1548-5315(11)70766-5","article-title":"Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice","volume":"1","author":"Fortner","year":"2004","journal-title":"Community Oncol"},{"key":"10.1016\/j.ygyno.2014.03.014_bb0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-4-22","article-title":"Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities","volume":"4","author":"Fortner","year":"2004","journal-title":"BMC Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814002509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814002509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:35:27Z","timestamp":1758771327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814002509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0090825814002509"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}